Age-Related Macular Degeneration | Current Treatment | US | 2016

Anti-vascular endothelial growth factor (VEGF) therapy is the standard of care for treating wet age-related macular degeneration (AMD), with several commercially available options. Use of off-label Avastin places pressure on the U.S. branded market; however, Eylea continues to gain market share. Additionally, with no currently available treatments, there is commercial opportunity for first-to-market dry AMD therapies. The Age-Related Macular Degeneration | Current Treatment overview provides a synopsis of current treatment goals, key therapies, and medical practice in the G7 markets, while the Dry and Wet Age-Related Macular Degeneration | Current Treatment | US detailed, expanded analysis offers a snapshot of how U.S. ophthalmologists prescribe currently available therapies as well as insight into the factors driving such prescribing habits.